Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449904 is registered in ClinicalTrials.gov with Anthera Pharmaceuticals as lead sponsor.

NCT NCT00449904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00449904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Lead sponsor
Anthera Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
April 30, 2009
Enrollment
214 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, exocrine pancreatic insufficiency